At the 2023 ASCO meeting, RudaCure registró an abstract for RCI002, its dolor inducido por quimioterapia tratamiento compuesto, and presentó the resultados preclínicos of the drug to many internacional investigadores.
En particular, this attendance was as part of the KONECT ensayo clínico delegation, which proporcionó a venue to discuss clinical topics related to ADC and CAR-T in the oncology field, along with related diseases and efectos secundarios, as well as an opportunity to introduce the eficacia of RCI002 in tratamiento del dolor.
RudaCure Clinical Director Yuseung Ha explaining RCI002 to a WRNMC Oncology Pharmacist
RCI002 Development Project Owner Manager Minjung Kim, Abbvie RA representative, WRNMC Pharmacist, Clinical Director Yuseung Ha
데일리팜: 데일리팜